Healthcare Industry News: Bard
News Release - July 2, 2007
Mentor Announces Market Launch of NeoForm(TM) Dermis for Breast ReconstructionSANTA BARBARA, Calif.--(HSMN NewsFeed)--Mentor Corporation (NYSE:MNT ), a leading supplier of aesthetic medical products in the United States and throughout the world, announced today the market launch of NeoForm(TM) dermis. NeoForm is processed by Tutogen Medical, Inc., and is a solvent-dehydrated, gamma-irradiated preserved human allograft dermis that is used in breast reconstruction procedures for women who have undergone a mastectomy.
The addition of NeoForm complements Mentor's line of high-quality breast reconstruction products, and it provides physicians and patients with another option that can help them achieve improved outcomes and greater patient satisfaction.
Joshua H. Levine, President and Chief Executive Officer of Mentor Corporation, stated, "NeoForm offers physicians a variety of benefits. NeoForm is ideal for breast reconstruction because it adds coverage and enables surgeons to define the shape and contour of the reconstructed breast. It also effectively supports and holds the tissue expander in place, and cushions the mastectomy skin envelope from contact with the expander."
For more information about NeoForm(TM) dermis, please contact Delia Cook, Senior Market Manager, Breast Aesthetics, at 805.879.6625.
About Mentor Corporation
Founded in 1969, Mentor Corporation is a leading supplier of medical products for the global aesthetic market. The Company develops, manufactures and markets innovative, science-based products for surgical and non-surgical medical procedures that allow patients to retain a more youthful appearance and improve their personal well-being. The Company's website is www.mentorcorp.com.
About Tutogen Medical, Inc.
Tutogen Medical, Inc. manufactures sterile biological implant products made from human (allograft) and animal (xenograft) tissue. Tutogen utilizes its Tutoplast Process® of tissue preservation and viral inactivation to manufacture and deliver sterile bio-implants used in spinal/trauma, urology, dental, ophthalmology and general surgery procedures. Tutogen's Tutoplast® products are sold and distributed worldwide by Zimmer Spine and Zimmer Dental, subsidiaries of Zimmer Holdings, Inc., Davol Inc. subsidiary of C.R. Bard Inc., Mentor Corporation, Coloplast Corp., IOP, Inc. and through independent distributors internationally. For more information, visit Tutogen's website at http://www.tutogen.com.
Safe Harbor Statement
This press release contains "forward-looking statements", including, statements regarding the market launch of NeoForm by Mentor. These forward-looking statements are based on our current expectations, estimates and projections about our industry, management's beliefs and certain assumptions made by us. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements speak only as of the date hereof and are based upon the information available to us at this time. Such information is subject to change, and we will not necessarily inform you of such changes. These statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statement as a result of various factors.
The Securities and Exchange Commission filings of Mentor, including, without limitation, its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and recent Current Reports on Form 8-K, discuss important risk factors that could contribute to such differences or otherwise affect its business, results of operations and financial condition. Mentor undertakes no obligation to revise or update publicly any forward-looking statement for any reason.
Source: Mentor Corp
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.